Recipharm
192 articles about Recipharm
-
RS BioTherapeutics Selects Recipharm as Product Characterization PartnerTakes important step towards filing an IND for RSBT-001 in the treatment of COPD
11/14/2022
RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has selected Recipharm, a leading Contract Development and Manufacturing Organization (CDMO).
-
The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
Acerus Commences Litigation in the U.K. Against Recipharm Over Estrace® Manufacturing Disruption
6/18/2020
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB (RECI-B.ST), in the Commercial Court of London. Acerus alleges that the suspension of Recipharm’s manufacturing lice
-
Recipharm supports FDA approval of Perrigo’s AB-rated generic product
3/12/2020
Recipharm, a leading contract development and manufacturing organisation, is pleased to note the FDA’s approval of Perrigo’s AB-rated generic of ProAir HFA.
-
Recipharm names 2019 International Environmental Award winner
2/24/2020
Recipharm has announced its 2019 International Environmental Award will be presented to Dana Kolpin, Research Hydrologist at the U.S. Geological Survey Central Midwest Water Science Center in Iowa City, Iowa.
-
Recipharm AB publishes report for the fourth quarter and full year 2019
2/20/2020
“The good performance we saw in the third quarter has continued to further improve.
-
Consort Medical becomes part of the Recipharm Group
2/4/2020
Recipharm announced on 4 February 2020 that the offer to acquire Consort Medical plc had become unconditional in all respects and will remain open for acceptances for a further 14 days, until 18 February 2020.
-
Recipharm acquires shares in Consort Medical
1/22/2020
Recipharm announces that it has this morning acquired 4,881,437 Consort Shares, representing 9.9 per cent. of the existing issued share capital of Consort Medical, at 1,010 pence per share and a further 118,563 Consort Shares, representing 0.2 per cent. of the existing issued share capital of Consort Medical at 1,000 pence per share.
-
Recipharm extends the acceptance period for the offer to acquire Consort Medical and updates on level of acceptance
1/14/2020
On 6 December 2019, Recipharm AB, through its directly wholly-owned subsidiary Recipharm Holdings Limited, published an offer document setting out the full terms and conditions of its recommended cash offer to acquire the entire issued and to be issued share capital of Consort Medical plc.
-
Recipharm receives competition clearance from German competition authorities for the offer to acquire Consort Medical
1/14/2020
Recipharm AB, through its directly wholly-owned subsidiary Recipharm Holdings Limited, published an offer document setting out the full terms and conditions of its recommended cash offer to acquire the entire issued and to be issued share capital of Consort Medical plc .
-
Recipharm partners with Aptahem for formulation of Apta-1 drug candidate
12/17/2019
Recipharm, the contract development and manufacturing organisation has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.
-
Recipharm invests in its US inhalation development service
12/9/2019
Recipharm, the contract development and manufacturing organisation, has invested USD 450,000 into its Research Triangle Park, North Carolina, US facility to install a SprayVIEW® system that will support inhalation and nasal product development.
-
Recipharm announces commercial manufacturing to support Talicia® Q1/2020 Launch following U.S. FDA approval
11/27/2019
Recipharm announced today ongoing large-scale commercial manufacturing of RedHill Biopharma’s (Nasdaq: RDHL) drug, Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg[1]/250 mg/12.5 mg, for its planned launch in the first quarter 2020.
-
Larger institutional shareholders support Recipharm’s cash offer for Consort Medical and subsequent rights issue
11/26/2019
Certain of Recipharm’s larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden, support the cash offer for Consort Medical and have undertaken to fully support and vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to at least their respective pro rata share in a rights issue of SEK 2,000 million.
-
Recipharm to communicate new financial targets on Capital Markets Day
11/18/2019
has continued to grow and will present its strategy for profitable growth moving forward, together with new financial targets from 2020, at Capital Markets Day in Stockholm.
-
Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player
11/18/2019
Recipharm AB and Consort Medical plc have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort, a leading global drug delivery and device company and integrated contract development and manufacturing organisation
-
Recipharm joins the AMR Industry Alliance
11/14/2019
Global contract development and manufacturing organisation Recipharm, has announced that it is joining the AMR Industry Alliance as part of its ambition to contribute to exploring solutions to tackle growing concerns around antimicrobial resistance
-
Recipharm AB publishes its interim report January - September 2019
11/7/2019
The good performance we saw in the second quarter has continued and further improved.
-
Recipharm launches Recipharm Analytical Solutions™ as its stand-alone offering for analytical chemistry
11/4/2019
Recipharm, the contract development and manufacturing organisation, has launched Recipharm Analytical Solutions™, a stand-alone service to support pharmaceutical companies with their Quality Control and analytical requirements.